The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Top Cited Papers
- 1 August 2001
- journal article
- clinical trial
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 18 (2) , 254-261
- https://doi.org/10.1183/09031936.01.00092101
Abstract
The clinical benefit and steroid-sparing effect of treatment with the anti-immunoglobulin-E (IgE) antibody, omalizumab, was assessed in patients with moderate-to-severe allergic asthma.Keywords
This publication has 29 references indexed in Scilit:
- Treatment of Allergic Asthma with Monoclonal Anti-IgE AntibodyNew England Journal of Medicine, 1999
- Allergic inflammation in upper and lower airwaysAnnals of Allergy, Asthma & Immunology, 1999
- IMMUNOLOGIC BASIS OF ANTIGEN-INDUCED AIRWAY HYPERRESPONSIVENESSAnnual Review of Immunology, 1999
- Effect of Inhaled Formoterol and Budesonide on Exacerbations of AsthmaNew England Journal of Medicine, 1997
- Current best practice for nebuliser treatment. British Thoracic Society Nebulizer Project Groupx [published erratum appears in Thorax 1997 Sep;52(9):838]Thorax, 1997
- Sorting out the cytokines of asthma.The Journal of Experimental Medicine, 1996
- Relationship between serum IgE and airway responsiveness in adults with asthmaJournal of Allergy and Clinical Immunology, 1995
- Anti-lgE Monoclonal Antibodies that Inhibit Allergen-Specific Histamine ReleaseInternational Archives of Allergy and Immunology, 1995
- A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroidClinical and Experimental Allergy, 1992
- Association of Asthma with Serum IgE Levels and Skin-Test Reactivity to AllergensNew England Journal of Medicine, 1989